This innovative therapy cleverly combines the "weight reduction and blood glucose lowering" effects of GLP-1R and GIPR co activation with the "enhanced insulin sensitivity and regulation of dyslipidemia" characteristics of PPAR activation
The most frequent adverse effects are gastrointestinal and dose-related: Nausea, vomiting, diarrhoea, constipation, and abdominal discomfort - Typically worst during dose escalation and often resolve or attenuate with continued treatment and slower titration
Providers will be able to prescribe comprehensive plans that pair FDA-approved GLP-1 medications with 24/7 care team access and educational support across nutrition and physical wellness
Integrative Potential and Clinical Insight From a functional medicine perspective, GLP-1, GLP-2, and VIP peptides could become adjunctive supports in MCAS and related conditions such as IBS, POTS, EhlersDanlos syndrome, chronic fatigue, and long COVID, where mast-celldriven neuroinflammation plays a central role
Amino Acids 39:321333 Salomons GS, van Dooren SJM, Verhoeven NM et al (2001) X-linked creatine-transporter gene (SLC6A8) defect: A new creatine deficiency syndrome
Multiomics, miRNAs, gene-editing technologies and epigenetic targets have received considerable attention but have yet to deliver usable therapies